AbbVie’s Immunology and Neuroscience Units Fuel Double-Digit Revenue Growth in Q1 2026; Full-Year Outlook Raised
Record Immunology and Neuroscience Sales Drive 12.4% Revenue Growth
AbbVie’s Q1 2026 financial report highlights a strong start to the year, anchored by exceptional performances in the immunology and neuroscience portfolios. Net revenues hit $15.00 billion, marking a 12.4% increase from the year-ago period (10.3% on an operational basis). Adjusted diluted EPS rose 7.7% to $2.65, with business momentum more than offsetting a $0.41 per share unfavorable impact from acquired IPR&D and milestones expense.
Skyrizi and Rinvoq Shine, Humira Declines as Portfolio Rotation Accelerates
Immunology remains AbbVie's cornerstone, delivering $7.29 billion in net revenues—up 16.4%. Skyrizi led the charge with a 30.9% reported increase to $4.48 billion, while Rinvoq grew 23.3% to $2.12 billion. Both products are supported by new indications and FDA submissions, reinforcing AbbVie’s immunology pipeline for years to come. However, legacy product Humira declined by 38.6%, reflecting the company’s transition in this space.
Neuroscience Surges on Strong Vraylar and Botox Therapeutic Growth
Neuroscience generated $2.88 billion in Q1 revenue, up 26.0% year-over-year. Vraylar ($905 million, +18.4%), Botox Therapeutic ($1.01 billion, +16.5%), and migraine treatments like Ubrelvy ($339 million, +41.4%) and Qulipta ($296 million, +53.6%) showed robust demand. This momentum is underpinned by new dosing regimens, clinical data disclosures at major conferences, and expanded indications for core therapies.
Oncology and Aesthetics Show Mixed Trends Amid New Product Approvals
Oncology revenue slipped slightly to $1.63 billion, with notable growth for Venclexta ($770 million, +15.7%) and new FDA approval for its partnership with acalabrutinib in chronic lymphocytic leukemia (CLL). However, Imbruvica revenues fell sharply, down 24.7% year-over-year. In aesthetics, sales climbed 7.6% to $1.19 billion, propelled by Botox Cosmetic (+20.2%) offsetting a flat Juvederm performance.
| Segment | Net Revenues (Q1 2026, $M) | % Change Y/Y | Key Drivers |
|---|---|---|---|
| Immunology | 7,290 | +16.4% | Skyrizi (+30.9%), Rinvoq (+23.3%), Humira (-38.6%) |
| Neuroscience | 2,875 | +26.0% | Vraylar, Botox Therapeutic, Ubrelvy, Qulipta |
| Oncology | 1,631 | -0.2% | Venclexta (+15.7%), Imbruvica (-24.7%) |
| Aesthetics | 1,186 | +7.6% | Botox Cosmetic (+20.2%) |
Operating Metrics Reflect Solid Profitability Despite R&D Investment
Adjusted gross margin was 83.6% and the adjusted operating margin stood at a robust 40.8%, reflecting exceptional operational efficiency amid increased R&D spending (15.1% of sales, adjusted). The adjusted tax rate for the quarter was a favorable 15.4%. Net interest expense increased slightly to $645 million, in part due to ongoing investments in manufacturing and new product launches.
2026 Guidance Raised as Pipeline and Business Investments Advance
Reflecting the company’s confidence, AbbVie raised its full-year 2026 adjusted diluted EPS guidance to $14.08–$14.28 (excluding yet-to-come IPR&D and milestones expenses). This outlook factors in anticipated regulatory milestones for Skyrizi (Crohn’s disease) and Rinvoq (severe alopecia areata), along with approvals of new oncology and aesthetics products. Notably, AbbVie is plowing $1.4 billion into a new manufacturing campus in North Carolina, and another $380 million for API facilities in Illinois, signaling visible long-term commitment to innovation.
Takeaway: Product Mix Resilience and Pipeline Progress Build for Long-Term Growth
AbbVie’s first-quarter performance highlights a new era—led by dynamic newer products rather than aging blockbusters. Skyrizi, Rinvoq, Vraylar, and the Botox franchises continue to offset Humira’s decline and anchor the company’s 2026 growth. With multiple FDA submissions, pipeline data readouts, and manufacturing investments ahead, investors and analysts may want to pay close attention to pipeline updates and regulatory catalysts that could shape the next phase of AbbVie’s trajectory.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI